Core Insights - ProMIS Neurosciences has completed enrollment for its PRECISE-AD Phase 1b trial, with 144 patients enrolled, exceeding the target of 128, indicating strong interest in PMN310's therapeutic potential [3][8] - The company reported a net loss of $39.7 million for the year ended December 31, 2025, with cash reserves of $6.1 million, reflecting its investment in advancing the PRECISE-AD trial [12][24] - PMN310 has shown a favorable safety profile with no treatment-related serious adverse events reported to date, and it is designed to minimize treatment-related side effects, particularly Amyloid-Related Imaging Abnormalities (ARIA) [4][15] Clinical Development - The PRECISE-AD trial is expected to complete six-month assessments in Q2 2026, with a blinded interim analysis anticipated in early Q3 2026 and top-line data expected in early 2027 [1][9] - PMN310 has been granted Fast Track Designation by the FDA, which may facilitate its development and regulatory engagement [7][15] - The company is also developing a subcutaneous formulation of PMN310 to improve patient experience and strengthen its competitive profile [6][13] Financial Overview - The company closed a financing round in early 2026, raising up to $175 million, which includes $75 million upfront and $100 million tied to future warrant exercises, providing a cash runway through 2027 [6][12] - Research and development expenses for 2025 were $33.4 million, significantly higher than the $10.6 million in 2024, primarily due to costs associated with the PRECISE-AD trial [12][24] - General and administrative expenses increased to $6.8 million in 2025 from $6.2 million in 2024, driven by a moderate increase in employee headcount [12][24] Pipeline and Future Directions - PMN267 and PMN442 are other key pipeline candidates targeting amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), respectively, with PMN267 showing selectivity for pathogenic TDP-43 and PMN442 targeting alpha-synuclein [13][14] - The company is monitoring developments in preclinical and asymptomatic Alzheimer's disease trials, considering potential expansion into these areas based on PMN310's safety profile [8]

Core Insights - ProMIS Neurosciences Inc. is advancing its lead clinical program PMN310 for Alzheimer's disease, with significant progress in patient enrollment for the PRECISE-AD trial, which is expected to yield interim results in the first half of 2026 and topline results by the end of 2026 [1][2][4] Alzheimer's Disease Program (PMN310) - PMN310 is a humanized IgG1 antibody targeting toxic amyloid-beta oligomers, which are believed to drive Alzheimer's disease [3] - The PRECISE-AD trial is a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetics of PMN310, with a planned enrollment of approximately 128 patients across 22 sites in the U.S. [3] - The trial aims to assess the incidence of ARIA (Amyloid-related imaging abnormalities) and other biomarkers, with a primary focus on safety [3][4] - The interim analysis in 2026 will provide early insights into PMN310's potential clinical benefits and tolerability [2][4] Financial Highlights - As of March 31, 2025, ProMIS reported cash and cash equivalents of $8.4 million, down from $13.3 million at the end of 2024 [12] - Research and development expenses increased to $5.5 million in Q1 2025, compared to $2.1 million in Q1 2024, primarily due to costs associated with the PMN310 Phase 1b clinical trial [12] - The net loss for Q1 2025 was $7.3 million, compared to a net loss of $3.6 million in the same period of 2024 [12][18] Other Programs - ProMIS is also advancing its Aβ vaccine program (PMN311) and has initiated a program targeting toxic misfolded TDP-43 for amyotrophic lateral sclerosis (PMN267) [4][5] - The company presented preclinical data at major conferences, highlighting the potential of its vaccine candidates to selectively target toxic oligomers and misfolded proteins associated with neurodegenerative diseases [7][8]

Core Insights - ProMIS Neurosciences Inc. is advancing its antibody therapeutics and vaccines targeting toxic misfolded proteins for neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) [1][9] - The company plans to present its findings at the 2025 Alzheimer's and Parkinson's Disease International Conference in Vienna, Austria, from April 1-4, 2025 [1][2] Research and Development - ProMIS has developed a computational modeling platform that aids in creating next-generation antibodies and targeted vaccines for neurodegenerative diseases [2] - Preclinical data suggests that vaccination with platform-derived epitopes and selective antibody targeting of misfolded toxic aggregates of TDP-43 may be a safe and effective treatment method [2] - The company identified four different conformational B cell epitopes of amyloid-beta oligomers (AβOs) through computational modeling, which are crucial in the development of an Alzheimer's vaccine [3] Preclinical Study Results - Immunization with a single conformational epitope, peptide 301, showed maximal reactivity against AD brain oligomers [4] - Vaccination against pathogenic species of alpha-synuclein (ASyn) demonstrated potential protection against synucleinopathies, preserving normal ASyn function while minimizing off-target effects [4][5] - The study on TDP-43 revealed that selective targeting of misfolded toxic aggregates could be a promising approach for treating diseases associated with TDP-43 proteinopathy [6][7] Product Information - PMN310 is a humanized monoclonal antibody designed to selectively target soluble amyloid-beta oligomers, which are believed to be the most toxic form of Aβ [8] - PMN310 has completed a Phase 1a clinical study and is currently in a Phase 1b clinical trial involving Alzheimer's disease patients [9]